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1. Introduction 
During several decades it was thought that in the adult, vascular growth and remodelling 
was exclusively dependent on the activation of angiogenesis, being the process of 
vasculogenesis restricted to embryonic life (Risau & Flamme, 1995; Risau, 1997). This 
long-lasting belief has come to an end in the late nineties, with the isolation from adult 
peripheral blood (PB) of angioblast-like circulating Endothelial Progenitor Cells (EPCs) 
(Asahara et al., 1997). The discovery of bone marrow (BM)-derived EPCs with angioblastic 
morphological and functional properties was a landmark in vascular biology that forever 
has changed the concept of neovascularization. Numerous studies have demonstrated 
that EPCs residing in the BM could be mobilized to the peripheral circulation, migrate to 
neoangiogenic sites and partake in vivo in the pathophysiological development of vascular 
networks, by differentiating into functional, mature endothelial cells (ECs) (Asahara et al., 
1999a, 1999b; Goon et al., 2007; Grant et al., 2002; Lyden et al., 2001; Takahashi et al., 
1999). However, much controversy has accompanied this field over time, particularly 
regarding the phenotypic characterization of EPCs. In fact, this cell population does not 
have specific cell surface markers, sharing a diversity of membrane receptors with other 
BM-derived cells (Hristov et al., 2003; Peichev et al., 2000). Additionally, several subsets of 
EPCs have been identified and together with other lineages of precursor cells were found 
to be differentially recruited to neovascular foci contributing synergistically to 
vasculogenic neoformation (Gulati et al., 2003; Hur et al., 2004; Lyden et al., 2001; Yoder et 
al., 2007; Yoon et al., 2005a). Since their identification, an increasing body of evidence has 
definitely revealed the important properties and roles played by EPCs in several vascular-
related diseases, such as peripheral vascular disease (Asahara et al., 1999a, 1999b; 
Takahashi et al., 1999), tumor neovascularisation (Asahara et al., 1999a, 1999b; Lyden et 
al., 2001) and vascular complications associated to diabetes (Goon et al., 2007; Grant et al., 
2002; Egan et al., 2008; Fadini et al., 2005). The metabolic alterations present in diabetic 
individuals are known to profoundly affect vascular biology, being responsible for the 
impairment of macro- and microvascular beds (Fadini et al., 2006a; Werner et al., 2005). 
Diabetes associated vascular complications involve distinct modifications in neovascular 
formation, which is reduced in ischemic heart and limbs and increased in the retina, 
defining the diabetic paradox (Ciulla et al., 2003). The vasculogenic process seems to play 
a central dual role in this paradoxal puzzle: systemically, diabetes-associated 
hyperglycemia, insulin resistance, hypertension and oxidative stress, can simultaneoulsy 
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injure the endothelium and deliteriously affect EPCs biological functions, impairing 
efficient systemic vascular repair and promoting peripheral vasculopathy (Povsic & 
Goldschmidt-Clermont, 2008); locally in the retina, the specific microenvironment may 
contribute to the local recruitment of EPCs, promoting increased vessel growth (Goon et 
al., 2007; Grant et al., 2002). Although still under investigation, these divergent features 
seem related to a differential regulation of neovascular mechanisms, which responde 
differently to ischemia-induced depletion of angiogenic factors in systemic conditions, or 
to the local induction of vascular growth factors in the diabetic retina (Duh & Aiello, 
1999). Due to the growing importance of vasculogenesis in diabetic vascular 
complications, interventions differentially modulating EPCs levels/functions may be 
regarded as therapeutic strategies. Systemically, vasculoprotective agents provided with 
beneficial cardiovascular effects, have showed to improve endothelium-dependent 
vascular function, by restoring EPCs properties and actions (Liang et al., 2009). Local 
delivery of anti-angiogenic drugs to the retina may have positive effects by hampering 
EPCs recruitment in proliferative diabetic retinopathy (PDR) (Chung et al., 2011). 
However, one might not neglect that diabetic patients frequently display both neovascular 
peripheral decrease and retinal increase of vessel growth. So, important questions are 
raised regarding the therapeutic use of EPCs in the promotion of periptheral 
vascularization and the impairment of EPCs-induced retinal neovascular formation and 
increased ischemia. Several issues need to be addressed in order to optimize the 
therapeutic use of EPCs and to get further information on the putative harmful side 
effects. Future research is mandatory in order to elucidate the complex molecular 
mechanisms governing the diabetic-vasculogenic paradigm, bringing novel insights into 
the safety on the therapeutic modulation of EPCs in diabetes vascular disorders. 
2. Endothelial progenitor cells (EPCs) and postnatal vasculogenesis  
Vasculogenesis and angiogenesis are the fundamental processes by which new blood 
vessels are formed. Vasculogenesis is defined as the differentiation of EPCs or angioblasts 
into ECs and the de novo formation of a primitive vascular network, whereas angiogenesis is 
the growth of new capillaries from pre-existing blood vessels (Risau & Flamme, 1995; Risau, 
1997). In the embryo, blood vessels form through both vasculogenesis and angiogenesis. 
Vasculogenesis occurs during early embryonic development and mediates the de novo vessel 
formation from angioblasts of mesodermal origin, which differentiate into mature ECs 
assembling into a primary capillary plexus (Risau & Flamme, 1995). Subsequently, this 
primitive vascular network expands by angiogenesis, where new blood vessels arise from 
the proliferation and migration of the pre-existing ECs (Folkman, 1984; Risau, 1997). During 
several decades it was thought that in the adult, vascular growth and remodelling was 
exclusively dependent on the activation of angiogenesis, and that the process of 
vasculogenesis was restricted to embryonic life. This prevailing dogma has come to an end 
over a decade ago, with the identification of circulating BM-derived EPCs in 1997 by 
Asahara and collaborators, which have isolated a population of angioblast-like CD34+ 
circulating EPCs from adult PB. In in vitro cultures, these cells presented an increased 
proliferation rate and exhibited endothelial morphological and functional properties 
(Asahara et al., 1997). However, this pioneering work was criticized and the true identity of 
the putative EPCs was questioned. In fact, besides the functional characteristics of these 
progenitor cells, namely their high proliferative capacity, this report did not provide any 
additional information regarding other specific functional characteristics. Additionaly, in 
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Asahara’s work the CD34 antigen was used to select EPCs, however the authors did not 
present a defined set of other phenotypic markers that could unambiguously identify this 
cell population allowing their sole isolation. In fact, CD34 is also expressed in sub-groups of 
hematopoietic stem/progenitor cells and mature ECs and does not specifically discriminate 
EPCs. Nevertheless, the work of Asahara et al. set a landmark in the field of vascular 
biology, for being the first to suggest that vasculogenesis could occur during adult life. 
Besides the controversy, after this initial report, a boom of novel studies corroborated 
Asahara’s hypothesis, presenting novel evidence for the existence of postnatal EPCs and 
their functional role in pathophysiological neovascular processes. Several reports 
demonstrated that a population of EPCs residing in the BM could be mobilized to the 
peripheral circulation, migrate to neoangiogenic foci and partake in vivo in the development 
of vascular networks, by differentiating into functional matured ECs and incorportating the 
vasculature (Asahara et al., 1999a, 1999b; Lyden et al., 2001; Shi et al., 1998). EPCs 
mobilization from the BM and homing to neovascular foci occurred in response of 
progenitor cells to specific angiogenic stimuli. The initial steps in mobilization involved the 
activation of matrix metalloproteinase (MMP)-9, which catalyses the conversion of 
membrane-bound Kit ligand to soluble Kit ligand. The subsequent cKit-positive progenitor 
cells are disengaged and can then move from the osteoblastic to the vascular zone of the BM. 
This process is enhanced by elevated levels of the chemokines Stromal Derived Factor 
(SDF)-1 and Vascular Endothelial Growth Factor (VEGF) (Heissig et al., 2002) and appears to 
be endothelial Nitric Oxide (eNO) dependent (Aicher et al., 2003). Increased eNO levels 
stimulate the passage of EPCs through BM sinusoidal endothelium and their entrance in the 
blood stream, where they are further recruited to neoangiogenic foci (Aicher at el., 2003, 
2005).  
3. EPCs phenotypic and functional properties  
Since their identification, the phenotypic characterization of EPCs has emerged a major 
setback in the field. Their isolation, identification and characterization were mostly 
hampered by the lack of EPCs-specific surface markers. Over time some consensus has 
apparently been reached and EPCs were considered to be the cell population characterized 
by the concomitant expression of: the early hematopoietic stem cell markers CD34 and 
CD133 (former AC133) and VEGF receptor-2 (VEGFR-2) (Hristov et al., 2003; Peichev et al., 
2000). However, it has been suggested that human CD34+CD133+VEGFR2+ cells comprise a 
population of cells that are not only EPCs, but distinct primitive hematopoietic progenitors, 
which also express markers such as CD45 and are devoid of vessel formation capabilities 
(Case et al., 2007; Timmermans et al., 2007). Other findings have demonstrated the existence 
of novel subsets of progenitor cells with an involvement in vascular repair. It was reported 
the presence in PB of a stem cell population which lack the CD34 antigen and is able to 
differentiate into CD34+CD133+ EPCs, and acquire a more mature endothelial phenotype 
(Friedrich et al., 2006). Additionally, other populations with endothelial repair capabilities 
which express additional cell surface markers, including the receptor for SDF-1, the 
chemokine (C-X-C motif) receptor (CXCR)-4 have also been identified (Egan et al., 2008). 
The characterization of these different subpopulations of EPCs is due to the different 
methodology used for cell isolation. To date, there are three main techniques that have been 
used to select, identify and characterize EPCs (Hirschi et al., 2008; Yoder, 2009). The cell 
types isolated using the different protocols are not phenotypically similar and as such, their 
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potential to influence neovascularization and/or vascular repair may vary. Consequently, 
this may offer an explanation as to the differences observed amongst similar studies which 
presented divergent results. 
3.1 Methods for EPCs isolation and characterization 
3.1.1 Culture of isolated mononuclear cells  
This method involves the isolation of mononuclear cells from PB or BM using density 
gradient centrifugation and the platting of these cells on fibronectin-coated substracts and 
cultured in medium supplemented with endothelial growth factors. Approximately 3 days 
later, non-adherent cells are removed from the culture and fresh media is added to the 
remaining cells which continue to be cultured and futher analysed. These spindle shaped-
adherent cells express EC markers and functional qualities, such as endocytosis and 
acetylated low-density lipoprotein (LDL) uptake. However, unlike progenitor cells they 
display low proliferative capacity, cannot form EC tube-like structures in an in vitro 
angiogenesis assay model, but do display panleukocyte and monocytic/macrophage 
markers, such as CD14 and CD45 (Rehman et al., 2003; Zhang et al., 2006, 2007). In support 
of this finding, previous data showed that monocytes have high affinity for fibronectin, and 
that 90% of cells from PB samples which adhere to coated dishes are of monocytic origin 
(Freundlich & Avdalovic, 1983). Moreover, a recent study by Prokopi et al. suggested how 
these putative EPCs may acquire EC markers. According to their data, the method used for 
mononuclear cell isolation from PB leads to the contamination of cells with platelets, which 
also express endothelial markers such as CD31 and von Willebrand factor (vWF) (Prokopi et 
al., 2009). During a 7 day mononuclear cell culture, the platelets are degraded into 
microparticles, vesicles which retain specific antigens from the cell of origin. So, adherent 
day 1 mononuclear cells presented as CD31 negative, but by day 7 expressed the CD31 
antigen, along with platelet-specific markers, following the uptake of degraded platelet 
microparticles and a transfer of cell antigens. Additionally, depletion of platelet 
microparticles from the EPCs culture media also removed the angiogenic properties often 
attributed to EPC culture medium, indicating that this in vitro property may be dependent 
on initial platelet presence following mononuclear cell isolation (Kirton & Xu, 2010; Rehman 
et al., 2003; Urbich et al., 2005). 
3.1.2 Fluorescence activated cell sorting (FACS) and in vitro culture 
One of the most currently used methods for EPCs separation, involves cell labelling with 
antigen specific antibodies and FACS analysis. This was the technique used by Asahara et al. 
in their pioneering work to isolate CD34+ mononuclear cells (Asahara et al., 1997). Since as 
aforementioned, CD34 does not selectively discriminate EPCs, following studies also 
included the use of CD133 combined with CD34 and VEGFR-2 (Peichev et al., 2000), to 
ensure that only progenitor cells were isolated as apposed to circulating ECs that have 
detached from the vessel wall (Blann & Pretorius, 2006; Ingram et al., 2005). These cells were 
cultured for 2 days and non-adherent cells re-plated for further 14 days, giving similar 
clustered colonies. Upon differentiating into mature ECs, EPCs lose the expression of CD133 
and start exhibiting classical EC morphology and features, such as the expression of the 
endothelial markers vWF and vascular endothelial cadherin (VE-cadherin) and the capacity 
to uptake acetylated LDL (Peichev et al., 2000; Shi et al., 1998). Several subsequent studies 
successfully isolated this cell type from adult PB, umbilical cord blood and fetal liver, using 
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a combination of these three markers (Timmermans et al., 2009). However, further 
controversy has arised since, it was reported that CD34+CD133+VEGFR2+ cells comprise a 
mixed population of EPCs and primitive hematopoietic progenitors, which express also 
CD45 and also lack the ability to form vessel-like structures (Case et al., 2007; Timmermans 
et al., 2007). 
3.1.3 In vitro colony forming cell assays 
Using this technique independent groups have shown that in adult PB mononuclear cells 
there are two distinct EPCs populations, which form in vitro Early Outgrowth Colonies 
(EOCs) and Late Outgrowth Colonies (LOCs) (Gulati et al., 2003; Hur et al., 2004). 
Additional studies have used different designations for these cell types: EOCs were also 
named early EPCs (eEPCs) and LOCs are also known as Outgrowth Endothelial Cells 
(OECs) (Medina et al., 2010, Yoon et al., 2005a) Although the biology of these endothelial 
progenitor-like cells is still under investigation, they seem to present different 
phenotypes, surface antigens and display diverse vasculogenic features in vitro. EOCs and 
LOCs are primarily characterized based on their morphology and chronology of 
appearance following in vitro culture. EOCs appear in culture within 7 days, emanating 
from a central cluster of cells, exhibiting spindle-shaped morphology and having a peak 
growth at 2-3 weeks after which they cannot be further expanded (Gulati et al., 2003; Hur 
et al., 2004). LOCs generally appear after 3 weeks and exhibit a “classic endothelial” 
phenotype, having an increased expansion potential. LOCs seem more capable of in vitro 
morphogenesis into capillary tubes, the best approximate true definition of an EPC, a 
competent progenitor cell whose terminally differentiated progeny are mature ECs 
(Gulati et al., 2003; Hur et al., 2004; Yoder et al., 2007). This capillary-forming capacity is 
minimal or nonexistent within EOCs, which are thought to have a paracrine role by 
supporting LOCs differentiation and capillary formation, through the release of pro-
angiogenic molecules and by inducing the activation of MMPs (Gulati et al., 2003; Hur et 
al., 2004; Yoon et al., 2005a). Phenotypically, EOCs additionally express the 
monocyte/macrophage marker CD14, which is absent among mature LOCs, and both 
populations may concomitantly express CD34 and VEGFR-2 (Yoon et al., 2005a). 
However, besides the reported alterations in phenotypic markers and the dissimilar 
biological properties, there was a lack of information regarding molecular differences 
between EOCs and LOCs. Recently, a study has provided a detailed molecular fingerprint 
of these two EPC subtypes, designated in this report by eEPCs and OECs. Medina and 
collaborators have shown that eEPCs and OECs have strikingly different gene/protein 
expression signatures (Medina et al., 2010). As evaluated by microarrays, many highly 
expressed transcripts in eEPCs were hematopoietic specific, including the Runt-related 
transcription factor (RUNX1) and the protein tyrosine kinase LYN; and with links to 
immunity and inflammation (Toll-Like Receptors, TLRs; CD14; Human Leukocyte 
Antigens, HLAs). On the other hand, OECs presented several highly expressed transcripts 
involved in vascular development and angiogenesis-related signaling pathways, such as 
the receptor tyrosine kinase Tie2, eNOS and Ephrins. Similarly, proteomic analysis 
revealed that 90% of spots identified by 2D gel electrophoresis analysis were common 
between OECs and endothelial cells while eEPCs shared 77% with monocytes. This study 
provided evidence that eEPCs are hematopoietic cells with a molecular phenotype linked 
to monocytes; whereas OECs exhibit commitment to the endothelial lineage, 
corroborating at the molecular level all the previous studies that have phenotypically 
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characterized these cell populations. These findings indicate that OECs are the subtype 
with vasculogenic capability and that functionally integrates neovascular foci, and it 
should be an attractive cell candidate for inducing therapeutic angiogenesis.  
Overall, these reports indicate that EPCs represent a heterogeneous population of cells, 
some of monocytic nature and others with a pro-angiogenic potential. Depending on the 
study model, cell isolation method and cell subtype used, the pro-angiogenic effects are a 
consequence of the direct vascular integration, the paracrine release of growth factors and 
cytokines, or the complex interactions with other cellular components like monocytes or 
platelets. Nonetheless, most of the reports involving in vitro and in vivo EPCs studies do not 
usually make a distinction between EOCs (eEPCs) and LOCs (OECs), analyzing both 
populations as a whole. As aforementioned, this may explain divergences observed amongst 
similar studies.  
4. Vasculogenesis and in vivo neovascular formation in pathophysiological 
processes 
Studies carried on experimental models have shown that postnatal vasculogenesis could 
take place under certain physiological and pathological settings. Further, it was also 
suggested that other BM-derived hematopoietic stem/myeloid progenitor cells, named as 
accessory cells, could be co-recruited to neoangiogenesis foci, and support vascular growth 
in a paracrine fashion through the release of pro-angiogenic factors or by contributing to 
extracellular matrix remodeling (De Palma et al., 2005; Fang & Salven, 2011; Grunewald et 
al., 2006; Kaplan et al., 2005; Lyden et al., 2001; Takakura, 2006). Due to the relevant role of 
neovascularization for tumor growth and metastization, several pre-clinical studies 
evaluated EPCs functions and their contribution for malignant development (Asahara et al., 
1999a, 1999b; Lyden et al., 2001). Additionally and corroborating experimental data, it was 
also reported that a percentage of BM-derived EPCs can integrate human tumour-associated 
neovasculature (Peters et al., 2005). Nonethess, despite all these evidence Purhonen et al. 
have suggested that BM-derived circulating EPCs do not contribute to vascular endothelium 
and are not needed for tumor development, raising novel controversy in the field (Purhonen 
et al., 2008). Besides tumor neovascular formation, further studies confirmed that EPCs play 
also a role in: vascular homeostasis and repair (Asahara et al., 1999a; Kirton & Xu, 2010; 
Shantsila et al., 2007), wound healing (Asahara et al., 1999b), bone regeneration (Matsumoto 
et al. 2008), myocardial infaction (Porto et al., 2011; Shintani et al., 2001), limb ischemia 
(Asahara et al., 1999a, 1999b; Takahashi et al., 1999), burn individuals and escharectomy 
(Foresta et al., 2011; Gill et al., 2001) and vascular complications associated to diabetes (Goon 
et al., 2007; Grant et al., 2002; Egan et al., 2008; Fadini et al., 2005).  
5. Vasculogenesis and the diabetic paradox  
Diabetes mellitus (DM) is a common costly chronic disease and its incidence is rapidly 
increasing worldwide. Once considered primarily as a risk factor for heart disease, diabetes 
has now become a high profile public health concern in its own right, due to the escalating 
epidemic of diabetes in older people, and the emergence of type 2 DM (T2DM) in children. 
In fact, individuals with T2DM account for most of this augmentation in the general 
population. An important part of this rise is attributed to changing living conditions, 
including overweight and obesity, sedentary behaviour, and unhealthy lifestyle (Perkins, 
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2004; Zimmet et al., 2001). Vascular complications in T2DM are a significant cause of human 
morbidity and mortality, by affecting multiple organs, in particular the cardiovascular 
system, through the promotion of atherosclerosis (Haffner et al., 1998; Nakagami et al., 2005; 
Werner et al., 2005). Diabetic vascular alterations in different organs occur by distinct 
modifications in neovascular formation, which is decreased in systemic cardiovascular 
disease (CVD) and increased in DR. This diabetic paradox has been attributed to the 
differential regulation of neovascular mechanisms, which responde differently to ischemia 
in diabetic conditions (Duh & Aiello, 1999). The vasculogenic process seems to play a central 
dual role in this paradoxal puzzle: by one hand diabetes-associated hyperglycemia, insulin 
resistance, hypertension and oxidative stress, can simultaneoulsy injure the endothelium 
and deliteriously affect EPCs functions, thus preventing efficient systemic vascular repair, 
favoring the development of peripheral vasculopathy (Povsic & Goldschmidt-Clermont, 
2008); on the other hand the specific retinal millieu may promote the local recruitment of 
EPCs, contributing to increased vessel growth in PDR (Goon et al., 2007; Grant et al., 2002). 
Althought the complex mechanisms governing this diabetic-vasculogenic paradox are still 
under investigation, novel evidence links alterations in EPCs biological functions to diabetic 
vascular complications, and will be further discussed.    
6. Diabetic vasculopathy and altered vasculogenesis 
Diabetes is characterized by a systemic pro-inflammatory state and generalized endothelial 
dysfunction (EDys). EDys ultimately represents the unbalance between endothelium injury 
and the endogenous capacity for endothelial repair (Costa et al., 2007). Compelling evidence 
suggested that hyperglycemia, insulin resistance, hypertension and oxidative stress, 
simultaneously promote endothelial damage and deliteriously affect EPCs functions, thus 
preventing efficient vascular repair and favoring the development of atherosclerotic lesions 
(Madonna & De Caterina, 2011; Povsic & Goldschmidt-Clermont, 2008). Amongst all these 
risk factors, increased glycemic levels and excessive oxidative stress seem to be the major 
causal factors underlying both endothelial injury and vasculogenic impairment (Callaghan 
et al., 2005). Nonetheless, the complex interplay between all the aforementioned conditions 
is thought to sinergistically decrease endothelial regeneration by altering EPCs biological 
activities, such as: reducing EPCs migration (Kränkel et al., 2005; Vasa et al., 2001); 
impairing their mobilization (Fadini et al., 2006b; Gallagher et al., 2007; Kang et al., 2009; 
Yao et al., 2006); promoting premature senescence (Higashi et al., 2002); inhibiting 
integrative and morphogenic capacities (defective adhesion, colony-forming ability and 
tubulization) (Fadini et al., 2006a; Tepper et al., 2002) and inducing EPCs apoptosis (Chen et 
al., 2010; Shen et al., 2010). These alterations on EPCs features have been associated with 
deficient endogenous re-endothelialization/neovascularization, being a potential indicator 
of diabetic CVD severity (Egan et al., 2008; Fadini et al., 2005; 2006b). In conjunction with 
deficient EPCs functions, the production of chemotactic/angiogenic factors is inhibited in 
diabetic peripheral ischemic tissues; contributing both to poor collateral formation and 
insufficient perfusion. It has been shown that the expression of angiogenic factors such as, 
VEGF and Hypoxia-Inducible Factor (HIF)-1 are reduced in the heart of diabetic patients 
during acute coronary syndromes (Marfella et al., 2004). Recently, it was also demonstrated 
that following the onset of acute myocardial infarction in T2DM patients, the numbers of 
CD133+ progenitor cells are reduced and their chemotactic responsiveness attenuated (Vöö 
et al., 2009). Both the defective expression of angiogenic factors and the dysfunction in EPCs 
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account for the delayed post-ischemic vascular healing and myocardial recovery in patients 
with DM. Diabetic cardiomyopathy is also characterized by an early and progressive decline 
in myocardial VEGF expression and reduced circulating EPCs, which contributes to 
diminished capillary density, decreased myocardial perfusion and impaired contractility 
(Yoon et al., 2005b). A significant decline in circulating EPCs was also reported in diabetic 
patients with peripheral arterial disease (PAD), particularly in individuals with ischemic 
foot lesions. EPCs levels correlated with the ankle-brachial index, the most objective 
diagnostic and prognostic test for lower extremity arterial disease. It was also demonstrated 
that decreased EPCs closely correlated with the severity of both carotid and lower limb 
atherosclerosis. Higher degrees of carotid stenosis, as well as, worse stages of leg 
claudication and ischemic lesions, were associated with lower levels of EPCs. This suggested 
that EPCs counts could be considered a valuable marker for atherosclerotic involvement 
(Fadini et al., 2005). Additionally, EPCs isolated from diabetic patients with PAD exhibited 
poor endothelial differentiation capacity, impaired proliferation and deficient adhesion to 
mature endothelium (Fadini et al., 2006a; 2006c). Recently, a study evaluated circulating 
levels of CD34-CD133+VEGFR-2+ EPCs in diabetic patients with CVD, revealing a decrease 
in this subpopulation caused by diabetes-induced apoptosis (Jung et al., 2010). Similarly, it 
was also proposed that a subset of CXCR-4+ progenitor cells with vascular repair capability, 
were decreased in the PB of T2DM patients (Egan et al., 2008). In ischemic conditions, 
reduced levels of CXCR-4+ precursors may responde poorly to SDF-1, preventing their 
efficient mobilization and recruitment from the BM niche to ischemic sites. In addition, it 
seems relevant to mention novel data disclosing the effects of hyperglycemia in EPCs in 
intrauterine life. Interestingly, the exposure to high glucose levels in a diabetic intrauterine 
environment was shown to diminish the clonogenic potential of neonatal EPCs, providing a 
new insight into the long-term cardiovascular complications observed in newborns of 
diabetic pregnancies (Ingram et al., 2008). Since it was reported that hyperglycemia, insulin 
resistance, hypertension and oxidative stress, are key factors on promoting endothelial 
damage and by altering EPCs functions, it will be further discussed how these conditions 
deleteriously affect vasculogenic events associated to peripheral vasculopathy (Madonna & 
De Caterina, 2011; Povsic & Goldschmidt-Clermont, 2008) 
6.1 Hyperglycemia  
Hyperglycemia is one of the major causal factors implicated in the development of 
vascular alterations (Aronson, 2008). High glucose levels are involved in the generation of 
advanced glycation end products (AGEs), which accumulate in the vessel wall, and by 
interacting with its receptors (RAGE) induce oxidative stress, increase inflammation and 
promote EDys (Jandeleit-Dahm & Cooper, 2008). Hyperglycemia is thought to maintain 
EDys conditions by directly impairing most EPCs-driven functional capabilities. 
Hyperglycemia was demonstrated to: decrease EPCs migration and integrative capacities 
(Kränkel et al., 2005); shift their differentiation into a pro-inflammatory phenotype 
(Loomans et al., 2009); reduce EPCs mobilization (Gallagher et al., 2007); accelerate the 
onset of progenitor cell senescence (Chen et al., 2007); induce apoptotsis (Chen et al., 
2010); inhibit EPCs colony-forming ability; decrease the number and proliferation of both 
early and late EPCs (EOCs and LOCs) and to impair the migration and vasculogenesis 
activities of LOCs, the subtype with vasculogenic-associated morphogenesis capability 
(Chen et al., 2007). Decreased vascular progenitor cells migration and inhibition of 
functional incorporation into tubular structures, were suggested to occur through 
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hyperglycemia-induced decrease in NO production and MMP-9 activity (Kränkel et al., 
2005). Reduced mobilization of EPCs was showed to occur due to modifications in eNOS 
phosphorylation and activation status within the BM microenvironment, unabling 
efficient EPCs release from the marrow niche to the peripheral circulation (Gallagher et 
al., 2007; Ingram et al., 2008). Hyperglycemia-induced EPCs senescence was demonstrated 
to take place through multiple mechanisms such as, by promoting telomere shortening, 
and alterations in the p38 MAPK and NO-mediated pathways (Chen et al., 2007; Ingram 
et al., 2008; Kuki et al., 2006). Additionally, a novel molecular link between high glucose 
levels and EPCs-increased senescence has been unveilled, as it was demonstrated that the 
Sirtuin 1 (SIRT1) gene, which regulates cell cycle, premature senescence and apoptosis, is 
downregulated in EPCs. SIRT1 low expression levels impair the important cascade of 
intracellular events, culminating with EPCs early senescence (Balestrieri et al., 2008a). 
Highlighting the crucial effects of high glicemic levels, it was also reported that the 
number of EPCs in T2DM was significantly decreased as compared with healthy controls. 
Additionally, an inverse correlation between EPCs numbers, plasma glucose and glycated 
hemoglobin (HbA1C) was found. Further, the number and function of EPCs in patients 
with good glycemic control were recovered compared with those with poor glycemic 
control. When glucose was supplemented to in vitro cultures, there was a negative effect 
on the proliferation and viability of EPCs, in a dose-dependent manner, whereas the 
enhancement of apoptosis was observed (Churdchomjan et al., 2010). All these deleterious 
effects were reported to occur due to a direct effect of elevated glucose levels on EPCs 
(Chen et al., 2007), however it was also suggested that hyperglycemia may promote EPCs 
dysfunction indirectly through the induction of Reactive Oxygen Species (ROS) 
overproduction and increased oxidative stress (Callaghan et al,. 2005). Moreover, anti-
diabetic treatments were reported to improve the re-endothelialization capacity of EPCs 
from diabetic individuals (Gensch et al., 2007). 
6.2 Insulin resistance (IR) 
Approximately 80% of all T2DM coexist with IR (Zimmet et al.; 2001). Several studies have 
proposed that IR may affect unfavourably the balance between endothelial injury and 
endogenous repair, promoting EDys and contributing to premature atherosclerosis (Dandona 
et al., 2003; 2004). Apparently, IR aids EDys perpectuation (Kim et al., 2006) by modulating 
vasculogenesis-associated EPCs capability of effectively promoting endothelium regeneration. 
Althought the direct mechanisms by which IR alters EPCs functions are still unclear, it was 
recently suggested that the chronic inflammatory environment present in T2DM leads to 
insulin signaling defects in EPCs, thereby reducing their survival (Desouza et al., 2011). 
Additionally, it was also reported that after arterial injury in hemizygous knockout mice for 
the insulin receptor (IRKO), EPCs activities were altered and endothelial regeneration delayed. 
This defective endothelial repair could be normalized by transfusion of progenitor cells from 
insulin-sensitive animals, but not from insulin-resistant animals (Kahn et al., 2011). However, 
it is thought that EPCs biological modifications are mostly affected by IR in an indirect fashion, 
through the increase in ROS and also by the activation of pro-inflammatory cytokines (Cubbon 
et al., 2007; 2009; Houstis et al., 2006). In fact, IR states are closely linked to the increased 
production of ROS, which is a characteristic feature of IR and thought to play a causal role in 
its development (Houstis et al., 2006). The deleterious effects of oxidative stress in EPCs 
biological characteristics have been established and will be contemplated in section 6.4. 
Although further direct cause-effect between IR and EPCs alterations is currently under 
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investigation, it has been shown that treatments with insulin sensitizing drugs may improve 
EPCs functional parameters, independently of glycemic levels and/or redox status 
(Schoonjans & Auwerx, 2001). Nonetheless, further studies are necessary to clarify the 
molecular links between IR and vasculogenic impairment.    
6.3 Hypertension 
High blood pressure levels are associated with significant mechanical endothelial injury and 
dysfunction (Spieker et al., 2000). Disruption of endothelial homeostasis in hypertensive 
patients is thought to worsen their cardiovascular prognosis (Perticone et al., 2001) and 
contribute to increased blood pressure levels (Schiffrin, 2001). Alterations in vasculogenesis-
related mechanisms have been associated to hypertension-induced EDys (You et al., 2008mi; 
Watson et al., 2008). A clinical study in patients with coronary artery disease (CAD) 
concluded that hypertension was a major independent risk factor predictor of impaired 
EPCs-induced migration (Vasa et al., 2001). It was reported that the functional activity of 
EPCs is reduced in experimental model settings and in hypertensive patients, due to 
increased EPC-induced senescence (Imanishi et al., 2005). Recently, it was shown that in vivo 
endothelial repair capacity of early EPCs was reduced in patients with pre-hypertension and 
hypertension, due to EPC senescence and impaired endothelial function, which potentially 
represents an early event in the development of hypertension (Giannotti et al., 2010). 
Although it is still unclear, hypertension does not seem to have a direct action on EPCs 
reduction of half-life, which may be caused by telomerase inactivation associated with the 
increase in oxidative stress associated with hypertension (Higashi et al., 2002; Imanishi et al., 
2005; Touyz et al., 2004). Further, studies showed that in patients with arterial hypertension, 
no association was observed between the number of circulating vascular progenitor cells 
and hypertension, suggesting that cell mobilization may not be affected (Delva et al., 2007; 
Werner et al., 2005). Inconsistently, it was also reported that reduced levels of circulating 
CD34+VEGFR-2+ EPCs were detected in hypertensive patients as compared to 
normotensive individuals (Pirro et al., 2007). Lower levels of peripheral EPCs correlated 
with a downregulation in the homeobox A9 (HOXA9) gene expression, which is critical for 
endothelial commitment during progenitor cell maturation (Pirro et al., 2007). Further 
studies are required to clarify the role of hypertension in EPCs functions. Nonetheless, it 
was also reported that anti-hypertensive drugs, besides its blood pressure lowering effect, 
may also improve vascular function through EPC activation (Cacciatore et al., 2011; de 
Ciuceis et al., 2011; Yao et al., 2007).   
6.4 Oxidative stress 
Increased oxidative stress has been proposed as an important molecular mechanism for 
vascular complications associated with DM, IR, and hypertension (Aronson, 2008; Houstis et 
al., 2006; Yanai et al., 2008), by exerting a direct cytotoxic effect on the vascular monolayer 
(Griendling & FitzGerald, 2003). ROS may directly harm the vascular endothelium while 
superoxide reacts with NO to form peroxynitrite anion (ONOO−), a powerful oxidant 
(Griendling & FitzGerald, 2003; Kuzkaya et al., 2003). Diminished release of eNO caused 
either by excessive oxidative degradation or impaired local production has been implicated 
in endothelial lining damage and insufficient repair capability due to deficient EPCs 
mobilization/functional status (Craeger et al., 2003; Yao et al., 2006). In fact, oxidative stress-
induced reduction of NO bioavailability represents the major mechanism leading to 
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impaired EPCs in vivo re-endothelialization capacity and in vitro function (Fleissner & 
Thum, 2010; Sorrentino et al., 2007). NO deficient release by the vasculature is thought to 
impair EPCs migratory function and colony-forming ability, indicating a central role for 
eNO activity in EPC biology in increased oxidative stress conditions (Hill et al., 2003). 
Additonally, it was recently shown in patients with metabolic syndrome (MetS) and CAD, 
that oxidative stress may directly induce DNA damage on EPCs, by promoting telomere 
shortening with a consequent increase in their senescence rate, which contributed to the 
progression of atherosclerosis (Fleissner & Thum, 2010; Satoh et al., 2008). Accordingly, anti-
oxidant therapies, which exert cellular protective effects by directly scavenging ROS 
reducing their damaging action, can also improve EPCs functions and regenerative abilities 
(Marrotte et al., 2010). 
7. EPCs and diabetic retinopathy (DR) 
DR, the leading cause of visual impairment in the western world, will occur in the majority 
of T1DM patients and about 20–30% will advance to the blinding stage of the disease. It is 
expected that over 60% of patients with T2DM will develop retinopathy and with the global 
epidemic of obesity and subsequently of T2DM this predicament is likely to worsen (Fong et 
al., 2002). Retinal neovascularization in diabetes is stringently affected by alterations in the 
local microenviroenment. Hyperglycemia damages retinal microvasculature, which results 
in increased permeability, blood and serum leakage to the extravascular space, and 
progressive decline in retinal blood flow; as well as closure of the retinal microvasculature 
leading to DR. Retinal ischemia and release of angiogenic factors stimulate the proliferation 
of microvessels, leading to proliferative DR (PDR). Dysfunctional new vessel growth 
destroys the normal retinal architecture and capillary leakage causes diabetic macular 
edema (DME), the principal cause of vision loss in diabetes (Li Calzi et al., 2010). Up until 
recently, angiogenesis was thought to be the only process governing aberrant diabetic 
retinal neovascularization. However, retinal ischemia-induced release of specific factors 
may stimulate both local growth of vessels and the mobilization of BM-derived EPCs, which 
contribute to the development of PDR. Initial studies in PDR experimental models have 
shown that EPCs could be recruited to retinal sites of ischemic injury, playing a role in the 
revascularization of the retina (Goon et al., 2007; Grant et al., 2002). Although the 
mechanisms underlying EPCs roles are still under evaluation, it was reported that they may 
be mobilized and recruited to the diabetic retina in response to local secretion of VEGF and 
SDF-1. Moreover, studies in PDR experimental models and in diabetic patients presenting 
this complication have shown that SDF-1 seems to be the most important chemokine 
involved in the mobilization of EPCs to the retina (Butler et al., 2005; Csaky et al., 2004). In 
addition, the concentration of SDF-1 increases with the severity of DR, as evaluated in 
vitreous samples of T2DM individuals (Butler et al., 2005). Recently, it was also proposed 
that retinal neuronal tissue could play a role in promoting EPCs-mediated 
neovascularization (Liu et al., 2010). This study has demonstrated that higher levels of the 
neurotrophins Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF) 
are present in the PB of DR patients, but not in non-diabetic controls or DM-PAD patients. 
Additionally, a strong correlation between these neurotrophins and EPC levels in DR 
patients was found, suggesting that retinal ischemia serves as a signal to stimulate BM-EPCs 
through selected strong neurotrophic factors that are released into the systemic circulation. 
Recently, two reports conveyed more important information on the role of different 
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progenitor cells in various stages of DR in T1DM and T2DM patients (Brunner et al., 2009, 
2011). In T1DM, it was demonstrated that in non-PDR patients there was a reduction in 
circulating EPCs, and that in PDR there was a dramatic increase of mature EPCs (Brunner et 
al., 2009). In addition, circulating EPCs of T1DM patients with PDR were reported to have 
increased clonogenic potential (Asnaghi et al., 2006). In T2DM patients with DR, circulating 
angiopoietic cells as EPCs, and mature EPCs had different regulations in PDR depending on 
each individual’s macrovascular comorbidities (Brunner et al., 2011). Recent findings in 
diabetic patients have corroborated gathered experimental data, demonstrating that BM-
derived CD133+ EPCs, as well as, CD14+ monocytes could be mobilized to diabetic 
epiretinal membranes, contributing to vasculogenesis in PDR (Abu El-Asrar et al., 2011). 
Taken together, these data strengthen the importance of EPCs in the development of human 
PDR, highlighting the crucial role played by both the local retinal and the systemic 
environment. 
8. Modulating EPCs functions as therapeutic strategy 
It seems paradoxal that diabetic vascular complications, as PDR and PAD, may both affect 
the same patient, and alterations in EPCs exhibit opposing roles. This contradictory 
puzzle will most certainly have an influence when considering the modulating of EPCs 
levels/functions as therapeutic intervention. It has been shown that several 
vasculoprotective agents provided with beneficial cardiovascular effects, such as statins, 
thiazolidinediones (peroxisome proliferators-activated receptor-gamma; PPAR-γ), and 
anti-oxidants have been shown to improve endothelium-dependent vascular function and 
prevent atherosclerotic disease progression, by restoring EPCs properties and actions 
(Chen et al., 2011; Kusuyama et al., 2006; Schoonjans & Auwerx, 2000). Additionally, and 
althougth there are no conclusive answers on the safety on EPCs therapies and of their 
potential undesidered side effects, pre-clinical and clinical studies have highlighted that 
autologous transplantation of several stem and progenitor cell populations ameliorated 
diabetic peripheral vascular complications (Procházka et al., 2009; Zhou et al., 2007). 
Nonetheless, the dysfunction of endogenous EPCs may limit the feasibility and efficiency 
of this approach, since their biological features are altered, which reduces their capacity to 
significantly improve therapeutic neovascularization. In addition, one might not neglect 
that there are several EPCs subtypes, which raises the question on what might be the best 
reparative BM-derived EPCs population (Figure 1). Further, would EPCs-based therapies 
provide any beneficial effects in retinal neovascularization? As aforementioned, retinal 
new vessel growth associated to diabetes is dysfunctional, destroying the normal retinal 
architecture. So we may assume that improving diabetic EPCs functions/transplanting 
non-diabetic EPCs to the retina may promote the re-endothelialization of acellular 
capillaries and the elimination of retinal ischemia. In fact, if intra-retinal 
neovascularization could be harnessed at the appropriate stage, ischemia could be 
contained or reversed (Figure 2). However, since the intravitreal delivery of anti-
angiogenic drugs may provide multiple benefits on DME and PDR (Arevalo et al., 2011; 
Chung et al., 2011), would the therapeutic use of EPCs be a better strategy for the 
treatment of DR? Many questions are still answered and in order to promote efficient 
EPCs-based therapies and to prevent harmful side effects, it is needed to go deeper into 
the molecular events accompanying alterations in diabetic vascular complications 
governing the diabetic-vasculogenic paradox.  
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Fig. 1. Diabetes and peripheral vasculopathy. Diabetes related metabolic disorders decrease 
EPCs number and function being associated with impaired re-endothelialization and 
neovascular formation. Several agents may increase EPCs functions improving their re-
vascularization capabilities. Adapted from Costa & Vendeira, 2007. 
 
 
Fig. 2. Diabetic retinopathy. The ischemic retinal microenvironment and the production of 
vascular and neurothrophic factors promote increased EPCs recruitment and dysfunctional 
neovascular formation. Anti-angiogenic agents may improve retinal vascular architecture. 
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9. Concluding remarks 
Even though EPCs constitute a relatively small percentage of circulating cells, they can 
specifically and effectively home to sites of injury and partake in the regeneration and repair 
of endothelial beds. Besides the initially identified population of CD34+AC133+VEGFR-2+ 
EPCs, other subsets of EPCs and progenitor cells with vascular repair capability have been 
described. We have discussed the most recent data demonstrating that dysfunctions of 
several EPCs subpopulations may have a prominent role in the pathogenesis of diabetes 
systemic and retinal vascular complications. Both the decrease and increase of neovascular 
formation in diabetes seem differentially regulated by dysfunctional EPCs, which respond 
selectively to the local depletion/accumulation of growth factors, explaining the reasons 
why peripheral ischemia cannot stimulate EPCs recruitment, in opposition to what occurs in 
the retina. Further studies are required to identify the beneficial effects/safety of EPCs-
based therapies. Additionally, it is mandatory to investigate the efficient use of EPCs in 
promoting neovascularization in peripheral vascular disease and the abrogation of retinal 
ischemia and altered vascular architecture. This carefull evaluation is crucial to further 
unveil the diabetic-vasculogenic paradox. 
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